SCHEMBL16355274

SCHEMBL16355274

c1ccc(-c2nc(-c3ccc(-c4c5ccccc5c(-c5cccc6ccccc56)c5ccccc45)cc3)nc(-c3cccc4ccccc34)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
KDM4E B2RXH2 3/20 0.50
TSHR P16473 2/20 0.50
MAPK1 P28482 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ATM Q13315 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TP53 P04637 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ADORA3 P0DMS8 1/20 0.41
ALOX15 P16050 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16355275 0.98 MAPT (0.49) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22766728 0.97 KDM4E (0.45) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL21309285 0.97 MAPT (0.53) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL16355276 0.95 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL16355277 0.95 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL16355269 0.95 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22766571 0.94 MAPT (0.48) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL23590347 0.93 MAPT (0.53) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22766715 0.92 MAPT (0.47) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL22722751 0.92 MAPT (0.54) MAPTSMN1; SMN2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9825244-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2017-11-21 US disclosed
US-9825244-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2017-11-21 US disclosed
US-20160308157-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO LTD (KR) 2016-10-20 US disclosed
US-20160308157-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO LTD (KR) 2016-10-20 US disclosed
US-9385336-B2 Organic light-emitting device using a mixture of electron transporting compounds SAMSUNG DISPLAY CO., LTD. (KR) 2016-07-05 US disclosed
US-9385336-B2 Organic light-emitting device using a mixture of electron transporting compounds SAMSUNG DISPLAY CO., LTD. (KR) 2016-07-05 US disclosed
US-20140374713-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2014-12-25 US disclosed
US-20140374713-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160308157-A1 ORGANIC LIGHT-EMITTING DEVICE ELMO1, ESR2, ELP1 MAPT 1382/4885SMN1; SMN2 1568/4885ALDH1A1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.